Last updated: July 31, 2026
Histrelin acetate is a long-acting gonadotropin-releasing hormone (GnRH) agonist marketed in the United States primarily as Supprelin LA for central precocious puberty (CPP). The same active ingredient was marketed as Vantas for palliative treatment of advanced prostate cancer. Supprelin LA remains the main commercial product, while histrelin’s clinical development is concentrated in pediatric endocrinology, prostate cancer, endometriosis, gender-affirming care, and other hormone-dependent conditions.
The product’s commercial position depends less on new molecular-drug exclusivity than on implant technology, specialist prescribing, procedural administration, limited competition, and manufacturing continuity. Public market reports generally aggregate histrelin into broader GnRH agonist or CPP categories rather than disclose histrelin-specific revenue.
What is histrelin acetate and how does it work?
Histrelin acetate is a synthetic GnRH agonist. Continuous exposure initially stimulates pituitary gonadotropin release, followed by downregulation of GnRH receptors and suppression of luteinizing hormone and follicle-stimulating hormone. The resulting reduction in sex-steroid production delays premature pubertal progression or suppresses androgen production.
The commercial dosage form is a subcutaneous implant containing 50 mg of histrelin acetate. Supprelin LA is designed to release histrelin continuously for approximately 12 months. Vantas used a comparable implant platform for androgen deprivation in prostate cancer.
| Product |
Active ingredient |
Dosage form |
FDA indication |
Administration |
| Supprelin LA |
Histrelin acetate |
50 mg subcutaneous implant |
Central precocious puberty |
Annual subcutaneous implant |
| Vantas |
Histrelin acetate |
50 mg subcutaneous implant |
Advanced prostate cancer palliation |
Annual subcutaneous implant |
Supprelin LA is administered by a trained healthcare professional. The implant is inserted subcutaneously, generally in the inner upper arm, and removed or replaced after approximately one year. The label identifies injection-site reactions, implant extrusion, implant migration, and procedural complications as relevant risks (FDA, 2023a).
What is the FDA regulatory status of histrelin acetate?
Supprelin LA was approved by the FDA in 2007 under New Drug Application 022058 for treatment of CPP. The approved population includes children with clinical and biochemical evidence of CPP.
Vantas was approved under NDA 021858 for palliative treatment of advanced prostate cancer. Its use was based on continuous testosterone suppression through the GnRH agonist mechanism.
| Regulatory asset |
NDA |
Sponsor or holder |
Indication |
FDA milestone |
| Supprelin LA |
022058 |
Endo Pharmaceuticals and related entities |
Central precocious puberty |
FDA approval in 2007 |
| Vantas |
021858 |
Endo Pharmaceuticals and related entities |
Advanced prostate cancer palliation |
FDA approval in 2004 |
Supprelin LA is an FDA-approved product and is listed in FDA drug databases. The product is not a biologic, so biosimilar substitution rules do not apply. Any competing product would generally follow an abbreviated or full drug-approval pathway depending on the formulation, reference-product status, and regulatory strategy.
What clinical trials are evaluating histrelin acetate?
Histrelin clinical research has historically focused on suppression of gonadal hormone production rather than expansion into a new chemical entity. The strongest evidence base is in CPP. Studies have also evaluated the implant in prostate cancer, endometriosis, uterine fibroids, transgender adolescent care, and other hormone-sensitive settings.
Central precocious puberty
Clinical trials and post-approval studies have assessed:
- Maintenance of estradiol or testosterone suppression.
- Advancement of bone age.
- Predicted adult height.
- Growth velocity.
- Pubertal staging.
- Duration of suppression across repeated annual implants.
- Safety of implant insertion and removal.
The annual implant provides a compliance advantage over monthly or three-month injectable GnRH agonists. The tradeoff is the need for a minor surgical procedure and a separate removal or replacement procedure.
Prostate cancer
Histrelin’s prostate-cancer development has centered on testosterone suppression and palliative androgen deprivation. The prostate-cancer market is substantially more competitive than the CPP market, with leuprolide, goserelin, degarelix, relugolix, and combination regimens competing across injectable and oral formats.
Histrelin is unlikely to become a major growth driver in prostate cancer without a new formulation, a differentiated administration schedule, or a combination strategy. Oral GnRH antagonists and next-generation androgen-receptor therapies have reduced the strategic importance of older annual GnRH agonist implants.
Endometriosis and other hormone-dependent conditions
Histrelin has been studied in endometriosis and uterine fibroids, but these uses have not created a comparable commercial franchise in the United States. Long-term GnRH agonist therapy is constrained by hypoestrogenic adverse effects, bone-density loss, vasomotor symptoms, and the need for add-back therapy in many patients.
Gender-affirming care
GnRH agonists, including histrelin implants, have been used off-label for pubertal suppression in transgender adolescents. This use is clinically important but is not the basis of the Supprelin LA FDA label. Coverage, state policy, institutional protocols, and payer authorization materially affect utilization.
ClinicalTrials.gov identifies historical and ongoing research involving histrelin, but the compound does not have the broad late-stage development profile associated with a pipeline drug. Current clinical value is primarily tied to approved CPP treatment and selected specialist uses (National Library of Medicine, 2024).
How large is the histrelin acetate market?
Public companies and market-research firms generally do not report histrelin acetate revenue as a standalone category. Supprelin LA sales are often embedded in specialty pharmaceutical or pediatric endocrinology reporting. Vantas has had a smaller and less strategically important commercial role than Supprelin LA.
The addressable market has three layers:
| Market layer |
Primary demand driver |
Competitive pressure |
| CPP |
Diagnosis rates, specialist referrals, insurance coverage, treatment duration |
Injectable GnRH agonists and alternative implants |
| Prostate cancer |
Androgen-deprivation therapy volume |
Leuprolide, goserelin, degarelix, relugolix |
| Off-label endocrine use |
Specialist practice and payer policy |
Other GnRH agonists and antagonists |
CPP is the most defensible segment because annual implant administration reduces adherence problems and creates a product-specific procedural workflow. The market is limited by the relatively small patient population and the availability of injectable alternatives.
A reasonable commercial projection is therefore a stable-to-low-growth profile rather than a high-growth pharmaceutical trajectory. Growth can come from increased CPP diagnosis, earlier referrals, broader payer coverage, and continued demand for long-acting treatment. Declines can result from supply interruptions, implant-site complications, procedural reluctance, and lower-cost injectable competition.
What patents protect histrelin acetate and Supprelin LA?
The relevant intellectual-property estate is expected to include several layers:
- The histrelin active ingredient and peptide chemistry.
- Controlled-release implant composition.
- Implant geometry and drug-release characteristics.
- Manufacturing, sterilization, loading, and packaging processes.
- Treatment methods using sustained histrelin exposure.
- Product-specific regulatory exclusivity and listed patent rights.
The original composition-of-matter protection for histrelin is no longer the principal barrier to entry. Commercial protection now depends on formulation, device, manufacturing know-how, regulatory requirements, and the difficulty of demonstrating equivalence for an implant.
How strong is the patent estate for histrelin acetate?
The estate is commercially meaningful but narrower than the patent position for a recently launched chemical entity. Implant products can retain practical barriers after basic drug patents expire because a competitor must reproduce:
- Consistent 12-month drug release.
- Sterile implant manufacture.
- In vivo pharmacokinetic performance.
- Reliable insertion and retrieval characteristics.
- Comparable suppression of sex-steroid production.
- A regulatory pathway acceptable to FDA.
The strongest protection is likely to reside in formulation and manufacturing know-how rather than in broad active-ingredient claims. Patent strength should therefore be assessed claim by claim through the FDA Orange Book, USPTO records, assignment data, and litigation history.
What is the Orange Book status of Supprelin LA?
Supprelin LA is an FDA-approved prescription drug listed in FDA drug databases. Orange Book analysis should distinguish between:
- Approved product listing.
- Patent listings for the specific NDA.
- Pediatric exclusivity.
- Regulatory exclusivity.
- Patent expiration.
- Any listed method-of-use claims.
FDA Orange Book patent listings can change through submissions, certifications, delistings, and administrative updates. The relevant commercial question is whether an ANDA applicant can obtain approval without infringing listed claims or whether a Paragraph IV certification would trigger litigation and a 30-month stay under the Hatch-Waxman framework (FDA, 2024).
When does histrelin acetate lose exclusivity?
Histrelin’s original market exclusivity has expired. The current risk analysis is therefore based on remaining patent claims, product-specific regulatory barriers, and commercial feasibility.
| Exclusivity category |
Current strategic relevance |
| Original active-ingredient patent |
Historical; no longer the primary barrier |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Historical periods may have applied; not a current barrier |
| Formulation patents |
Potentially relevant if listed and unexpired |
| Method-of-use patents |
Relevant only to covered indications and claims |
| Implant manufacturing know-how |
Potentially significant even without broad patent coverage |
| Regulatory approval |
Requires product-specific evidence and compliance |
Exact patent expiration dates must be confirmed against the current Orange Book and USPTO records because listed patents, terminal disclaimers, pediatric extensions, and patent-status changes can affect the operative date.
Which companies are challenging histrelin acetate?
No broadly established generic histrelin implant franchise has displaced Supprelin LA in the U.S. market. The principal competitive threats are indirect:
- Generic leuprolide injections.
- Goserelin implants.
- Degarelix injections.
- Oral relugolix for prostate cancer.
- Alternative long-acting endocrine therapies.
- Hospital or specialty-pharmacy purchasing pressure.
A direct histrelin implant entrant would face technical and commercial barriers. The product requires specialized sterile manufacturing, implant insertion training, removal logistics, and a distribution model capable of supporting pediatric endocrinologists and specialty pharmacies.
What patent litigation and Paragraph IV risks affect Supprelin LA?
The principal litigation risk would arise from an ANDA applicant filing a Paragraph IV certification against an Orange Book-listed patent. Potential disputes could concern:
- Implant drug-release kinetics.
- Polymer or excipient composition.
- Implant dimensions.
- Manufacturing process claims.
- Sterility and packaging.
- Method-of-treatment claims.
A successful Paragraph IV challenge could enable earlier generic entry, while settlement terms could delay launch through a negotiated date or impose licensing conditions. Publicly available information does not establish a current, market-defining Paragraph IV challenge that has materially displaced Supprelin LA.
How does histrelin compare with competing GnRH therapies?
| Attribute |
Histrelin implant |
Leuprolide injection |
Goserelin implant |
Relugolix tablet |
| Main delivery |
Annual subcutaneous implant |
Monthly to six-month injection |
Periodic implant |
Daily oral |
| CPP use |
Established with Supprelin LA |
Established |
Limited relative use |
Not standard |
| Prostate-cancer use |
Historical Vantas positioning |
Broad |
Broad |
FDA-approved |
| Administration burden |
Procedure and removal |
Repeated injections |
Procedure or insertion |
Daily adherence |
| Key advantage |
Long duration |
Broad availability |
Long-acting delivery |
Rapid, reversible suppression |
| Key limitation |
Implant procedure and supply dependence |
Repeated visits |
Procedure and device logistics |
Daily dosing and cardiovascular considerations |
Histrelin’s strongest differentiation is duration. Its weakest points are procedural dependence, limited scale, and competition from lower-cost or more familiar GnRH products.
What manufacturing and IP barriers affect generic launch?
A generic histrelin implant would need to establish pharmaceutical equivalence and demonstrate that its implant system produces the required release profile. The relevant technical risks include:
- Peptide stability during manufacturing.
- Uniform drug loading.
- Controlled diffusion over 12 months.
- Sterile processing.
- Packaging integrity.
- Implant migration or extrusion.
- Removal performance.
- Batch-to-batch release consistency.
These requirements can make a technically feasible generic unattractive if the market is too small to justify development and manufacturing investment. A competitor may instead pursue a 505(b)(2) application, a reformulated implant, or a different long-acting GnRH delivery system.
What is the outlook for histrelin acetate through 2030?
The base-case outlook is stable, supported by Supprelin LA’s established CPP position and the clinical value of annual dosing. The product is unlikely to generate substantial growth from new indications without a new clinical-development program.
| Scenario |
Commercial outcome through 2030 |
Main driver |
| Base case |
Stable or modest growth |
CPP demand and continued specialist use |
| Upside case |
Moderate growth |
Expanded pediatric diagnosis, payer access, or new indication |
| Downside case |
Declining revenue |
Supply disruption, direct implant competition, or migration to injectables |
| Disruption case |
Material erosion |
Successful generic implant or competing long-acting technology |
Revenue exposure is concentrated in CPP rather than prostate cancer. The largest near-term risks are supply continuity, reimbursement, procedure access, and direct or indirect competition from other long-acting GnRH therapies.
Key Takeaways
- Supprelin LA is the principal current commercial product containing histrelin acetate.
- Its FDA-approved indication is central precocious puberty.
- Vantas established a prostate-cancer use but is not the primary growth platform.
- The original histrelin composition-of-matter exclusivity is historical.
- Formulation, implant, manufacturing, and regulatory barriers are more important than the original molecule patent.
- No biosimilar pathway applies because histrelin is a synthetic peptide drug, not a biologic.
- Direct generic implant competition appears more difficult than competition from injectable and oral GnRH therapies.
- The market outlook is stable to modestly declining unless the sponsor expands indications or improves delivery.
- CPP accounts for the strongest commercial and clinical rationale for continued histrelin use.
Frequently Asked Questions
Is histrelin acetate a biologic drug?
No. Histrelin acetate is a synthetic GnRH agonist peptide regulated as a drug. Biosimilar approval rules do not apply.
Is Supprelin LA interchangeable with Lupron Depot?
No. Supprelin LA and Lupron Depot use different delivery systems, dosing schedules, formulations, and regulatory approvals. Substitution requires a clinician’s decision.
Is histrelin acetate approved for gender dysphoria?
Supprelin LA is not FDA-approved specifically for gender dysphoria. Histrelin implants have been used off-label for pubertal suppression in transgender adolescents.
Does histrelin acetate require annual surgery?
Supprelin LA requires insertion by a healthcare professional and generally requires removal or replacement after approximately 12 months.
What is the main investment risk for histrelin acetate?
The main risk is commercial erosion from alternative GnRH therapies or a competing implant, combined with manufacturing and supply-chain dependence for a technically complex annual-release product.
References
-
U.S. Food and Drug Administration. (2023a). Supprelin LA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022058s012lbl.pdf
-
U.S. Food and Drug Administration. (2023b). Vantas prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
National Library of Medicine. (2024). ClinicalTrials.gov: Histrelin studies. https://clinicaltrials.gov/search?term=histrelin
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
